TL;DR: The Centers for Medicare & Medicaid Services modified NCD 321 for nebulized beta adrenergic agonist therapy, effective January 9, 2026. CMS determined no national coverage determination is appropriate — which means your reimbursement and claim denial exposure depends entirely on your local Medicare Administrative Contractor.
This policy governs nebulized beta adrenergic agonist therapy for lung diseases including COPD and asthma, and it falls under the durable medical equipment benefit category. NCD 321 in the CMS system is a national coverage determination, but CMS has explicitly punted coverage decisions to local MACs. This policy does not list specific CPT or HCPCS codes. That absence is itself the story.
| Field | Detail |
|---|---|
| Payer | CMS |
| Policy | Nebulized Beta Adrenergic Agonist Therapy for Lung Diseases |
| Policy Code | NCD 321 |
| Change Type | Modified |
| Effective Date | 2026-01-09 |
| Impact Level | High |
| Specialties Affected | Pulmonology, Internal Medicine, Primary Care, DME Suppliers, Home Health |
| Key Action | Contact your MAC immediately to confirm local coverage determination requirements for nebulized albuterol and levalbuterol billing |
CMS Nebulized Beta Adrenergic Agonist Coverage Criteria and Medical Necessity Requirements 2026
The real issue with this coverage policy is what it doesn't do. CMS reviewed the medical evidence for nebulized beta adrenergic agonist therapy — including racemic albuterol and levalbuterol — and explicitly declined to set national coverage standards. Under Section 1862(a)(1)(A) of the Social Security Act, Medicare covers services that are "reasonable and necessary." CMS has decided not to define what that means for this therapy at the national level.
Instead, CMS has delegated all medical necessity determinations to local Medicare Administrative Contractors through the local coverage determination process or case-by-case adjudication. That's not a technicality. It means the coverage policy your billing team operates under depends on which MAC jurisdiction your claims fall into.
This matters especially for DME suppliers and practices billing for home nebulizers and the drugs used in them. Racemic albuterol has been the standard for years. Levalbuterol — the (R) enantiomer of racemic albuterol — has more recently entered use in specific patient populations, and CMS specifically flagged "concerns regarding the appropriate use" of these therapies. That language signals scrutiny, not permissiveness.
Don't assume national silence means national approval. When CMS says "no NCD is appropriate," it's not clearing the path — it's handing the gatekeeping to your MAC. Prior authorization requirements, documentation thresholds, and medical necessity criteria will vary by region.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Nebulized beta adrenergic agonist therapy for COPD | No NCD — MAC determines | Not specified in NCD 321 | Refer to your MAC's LCD for coverage criteria |
| Nebulized beta adrenergic agonist therapy for asthma | No NCD — MAC determines | Not specified in NCD 321 | Refer to your MAC's LCD for coverage criteria |
| Racemic albuterol via nebulizer | No NCD — MAC determines | Not specified in NCD 321 | Long-standing use; MAC adjudication applies |
| Levalbuterol via nebulizer | No NCD — MAC determines | Not specified in NCD 321 | CMS flagged appropriate-use concerns; expect MAC scrutiny |
| Nebulized bronchodilator for other lung diseases | No NCD — MAC determines | Not specified in NCD 321 | Case-by-case adjudication permitted under NCD 321 |
CMS Nebulized Beta Adrenergic Agonist Billing Guidelines and Action Items 2026
This is where the rubber meets the road for nebulized beta adrenergic agonist billing. The lack of a national standard doesn't reduce your exposure — it increases it, because you can't point to a single authoritative document when a claim is challenged.
| # | Action Item |
|---|---|
| 1 | Pull your MAC's current LCD for nebulized bronchodilators before January 9, 2026. The effective date of this NCD modification is January 9, 2026. Before that date, confirm which local coverage determination your MAC has in place and whether it has changed in response to this NCD update. Novitas, CGS, Palmetto, WPS, NGS, and First Coast all have separate processes. Don't assume your MAC's LCD is current or that it matches what a colleague at another practice is using. |
| 2 | Audit your documentation for levalbuterol claims specifically. CMS called out levalbuterol by name and flagged concerns about appropriate use. If your practice or your patients' DME suppliers are billing levalbuterol — which typically carries a higher cost than racemic albuterol — your medical necessity documentation needs to be airtight. The physician's chart should show why levalbuterol was chosen over racemic albuterol for that specific patient. |
| 3 | Confirm prior authorization requirements with your MAC. NCD 321 does not set prior authorization rules nationally. Your MAC may require prior auth for nebulizer equipment, for the drugs themselves, or for both. If your billing team is submitting claims without confirming current PA requirements, you're flying blind. Check now, not after the first denial. |
| 4 | Review your charge capture for DME-category drug billing. This policy sits in the durable medical equipment benefit category. If your practice supplies nebulizers directly or coordinates with a DME supplier, confirm that your charge capture reflects your MAC's current billing guidelines for both the equipment and the associated drug codes. A mismatch between the equipment claim and the drug claim is a common trigger for claim denial. |
| 5 | Talk to your compliance officer if you're billing levalbuterol at scale. If levalbuterol makes up a significant portion of your nebulizer drug billing, this NCD modification creates compliance exposure. CMS's language about "concerns regarding appropriate use" is the kind of phrasing that precedes targeted audits. Your compliance officer should be aware of this change and your billing patterns before January 9, 2026. |
| 6 | Set up a process to track MAC LCD updates going forward. Because NCD 321 places all coverage authority with MACs, any future LCD change from your contractor directly changes your coverage policy — without any corresponding NCD update from CMS. If you're not monitoring your MAC's LCD publications, you won't see changes coming. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Nebulized Beta Adrenergic Agonist Therapy Under NCD 321
Covered CPT and HCPCS Codes
This policy does not list specific CPT or HCPCS codes. NCD 321 does not designate any codes as nationally covered or non-covered. Your MAC's local coverage determination governs which codes are reimbursable in your jurisdiction.
For nebulized beta adrenergic agonist billing, the relevant codes are typically found in your MAC's LCD and associated billing guidelines for DME and inhalation drugs. Contact your MAC directly or review their posted LCDs on the CMS LCD database at cms.gov to get the current applicable codes for your region.
Not Covered / Experimental Codes
No codes are designated as nationally non-covered under NCD 321. CMS made no national non-coverage determination. MAC-level exclusions may apply — check your local coverage determination.
Key ICD-10-CM Diagnosis Codes
No ICD-10-CM codes are specified in NCD 321. Diagnosis code requirements for COPD, asthma, and related lung diseases are set by your MAC's LCD. Common diagnosis categories include COPD and asthma, but your MAC determines which specific ICD-10 codes qualify for coverage and which do not.
The honest read on NCD 321 is that it creates more work for billing teams, not less. A national non-decision sounds benign. In practice, it means 12 different MACs can reach 12 different answers on the same clinical scenario. Your reimbursement depends on which side of a jurisdictional line your patients live on.
For practices that span multiple MAC jurisdictions — or DME suppliers with a broad geographic footprint — this is a genuine operational challenge. You need to maintain separate documentation standards and prior authorization workflows for each MAC. That's not hypothetical; that's the direct consequence of CMS's decision here.
If you're unsure how this applies to your patient mix or your MAC's current LCD, talk to your billing consultant or compliance officer before January 9, 2026.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.